Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.42M | 54.55M | 56.42M | 62.30M | 80.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.42M | 54.55M | 56.42M | 62.30M | 80.89M |
| Cost of Revenue | 241.29M | 221.63M | 204.12M | 196.50M | 193.34M |
| Gross Profit | -184.87M | -167.08M | -147.70M | -134.19M | -112.45M |
| SG&A Expenses | 45.80M | 45.94M | 46.01M | 44.91M | 44.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 287.09M | 267.58M | 250.13M | 241.41M | 238.22M |
| Operating Income | -230.67M | -213.03M | -193.70M | -179.11M | -157.33M |
| Income Before Tax | -208.22M | -193.30M | -176.71M | -164.82M | -144.64M |
| Income Tax Expenses | 180.00K | 270.00K | 262.00K | 180.00K | 90.00K |
| Earnings from Continuing Operations | -208.40 | -193.57 | -176.98 | -165.00 | -144.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.40M | -193.57M | -176.98M | -165.00M | -144.73M |
| EBIT | -230.67M | -213.03M | -193.70M | -179.11M | -157.33M |
| EBITDA | -222.35M | -205.01M | -186.40M | -172.25M | -150.90M |
| EPS Basic | -2.81 | -2.89 | -2.91 | -2.92 | -2.65 |
| Normalized Basic EPS | -1.75 | -1.80 | -1.82 | -1.82 | -1.66 |
| EPS Diluted | -2.81 | -2.89 | -2.91 | -2.92 | -2.65 |
| Normalized Diluted EPS | -1.75 | -1.80 | -1.82 | -1.82 | -1.66 |
| Average Basic Shares Outstanding | 297.13M | 268.47M | 244.73M | 226.34M | 218.22M |
| Average Diluted Shares Outstanding | 297.13M | 268.47M | 244.73M | 226.34M | 218.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |